A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease
Open Access
- 1 April 2004
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 61 (4) , 561-566
- https://doi.org/10.1001/archneur.61.4.561
Abstract
Research from JAMA Neurology — A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson DiseaseKeywords
This publication has 7 references indexed in Scilit:
- Mitochondrial permeability transition mediates apoptosis induced by N‐methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl‐2 and rasagiline, N‐propargyl‐1(R)‐aminoindanJournal of Neurochemistry, 2002
- The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in VivoAnnals of the New York Academy of Sciences, 2001
- Mechanism underlying anti-apoptotic activity of a (−)deprenyl-related propargylamine, rasagilineMechanisms of Ageing and Development, 2000
- Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouseEuropean Journal of Pharmacology, 1999
- Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-BEuropean Journal of Pharmacology, 1985
- TYRAMINE ANTAGONISTIC PROPERTIES OF AGN 1135, AN IRREVERSIBLE INHIBITOR OF MONOAMINE OXIDASE TYPE BBritish Journal of Pharmacology, 1981
- ParkinsonismNeurology, 1967